One could wish/expect a solid,objective evaluation/valution of Teva...As what we get from time to time is often tainted or myopic.This will not do for company of this size and importance !!! Any volunteers??? Professionals or others ???
DJIA: 12,830.52 -140.54 (-1.08%) | NASDAQ: 2,903.39 -16.82 (-0.58%) | S&P 500: 1,360.21 -14.93 (-1.09%) —Markets close in 3 hrs 42 mins Print Format Change Text Size: Default text sizeA Larger text sizeA Largest text sizeA Teva Pharmaceutical Reports Q2 EPS In Line, Revenues Just Shy of Estimates; Reaffirms FY12 Outlook In Line; Shares Inch Up in Pre-Market BY Midnight Trader — 8:06 AM ET 08/02/2012 08:06 AM EDT, 08/02/2012 (MidnightTrader) -- Teva Pharmaceutical Industries (TEVA
Loading... ) today reported Q2 earnings of $1.28 per share, ex one-time items, in line with the Capital IQ consensus of $1.28. Revenues were $4.99 mln, versus the analyst estimate of $5.09 mln. The company maintains its FY12 EPS outlook of $5.30 - $5.40, ex special items, in line with the consensus of $5.38. Revenues are expected to be $20 bln - $21 bln, also in line with the consensus of $20.59 bln. Shares are up 0.07% to $40.90 in the pre-market session, with a 52-week range of $35.00 - $46.65. Price: 40.90, Change: +0.03, Percent Change: +0.07 http://bit.ly/H4yNQN
This news story has 3 comments:
DJIA: 12,830.52 -140.54 (-1.08%) | NASDAQ: 2,903.39 -16.82 (-0.58%) | S&P 500: 1,360.21 -14.93 (-1.09%) —Markets close in 3 hrs 42 mins
Print Format Change Text Size:
Default text sizeA Larger text sizeA Largest text sizeA
Teva Pharmaceutical Reports Q2 EPS In Line, Revenues Just Shy of Estimates; Reaffirms FY12 Outlook In Line; Shares Inch Up in Pre-Market
BY Midnight Trader
— 8:06 AM ET 08/02/2012
08:06 AM EDT, 08/02/2012 (MidnightTrader) -- Teva Pharmaceutical Industries (TEVA
Loading...
) today reported Q2 earnings of $1.28 per share, ex one-time items, in line with the Capital IQ consensus of $1.28. Revenues were $4.99 mln, versus the analyst estimate of $5.09 mln.
The company maintains its FY12 EPS outlook of $5.30 - $5.40, ex special items, in line with the consensus of $5.38. Revenues are expected to be $20 bln - $21 bln, also in line with the consensus of $20.59 bln.
Shares are up 0.07% to $40.90 in the pre-market session, with a 52-week range of $35.00 - $46.65.
Price: 40.90, Change: +0.03, Percent Change: +0.07
http://bit.ly/H4yNQN